Blueprint Medicines (BPMC) Reports Q2 Loss of $0.62/Share

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.62), versus ($0.86) reported last year. Revenue for the quarter came in at $41.44 million, versus $5.89 million reported last year.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance